Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Healthcare Opportunities Fund offers a compelling way to play the healthcare sector. Read here for an analysis of THQ CEF.

The medical world relies on horseshoe crab blood in the production of vaccines and equipment. A synthetic is available, but ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for beginners. On August 13, Cantor Fitzgerald ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly & Co. raises Mounjaro prices in the United Kingdom to reduce costs in the U.S. Weight-loss drug prices increase by 170% in the U.K., but its National Health Service prices remained unchanged ...

It seems to be holding off on price adjustments demanded by President Trump.

Eli Lilly recently spoke out against proposed tariffs on pharmaceuticals, warning they could increase drug costs and restrict patient access. The drugmaker said it has invested more than $50 billion ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...